• +1-646-491-9876
    • +91-20-67278686

    Search

    Rhinovirus Infections - Pipeline Review, H1 2017

    Rhinovirus Infections - Pipeline Review, H1 2017

    • Report Code ID: RW0001709460
    • Category Pharmaceuticals
    • No. of Pages 49
    • Publication Month Mar-17
    • Publisher Name Global Markets Direct
    Rhinovirus Infections - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Rhinovirus Infections - Pipeline Review, H1 2017, provides an overview of the Rhinovirus Infections (Infectious Disease) pipeline landscape.

    Rhinoviruses are common cause of the common cold. The virus can spread through droplets in the air when someone who is sick coughs, sneezes or talks. Symptoms include sore throat, runny nose, sneezing, fatigue, headache and loss of appetite. Risk factors include age and weakened immune system. Treatment includes pain relievers and decongestant medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Rhinovirus Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Rhinovirus Infections (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Rhinovirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rhinovirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 6 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

    Rhinovirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Rhinovirus Infections (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Rhinovirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Rhinovirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Rhinovirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Rhinovirus Infections (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Rhinovirus Infections (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Rhinovirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Rhinovirus Infections - Overview
    Rhinovirus Infections - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Rhinovirus Infections - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Rhinovirus Infections - Companies Involved in Therapeutics Development
    AIMM Therapeutics BV
    AstraZeneca Plc
    Aviragen Therapeutics Inc
    Biological Mimetics Inc
    Boehringer Ingelheim GmbH
    Novartis AG
    Prokarium Ltd
    Rhinovirus Infections - Drug Profiles
    BNT-014 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cetylpyridinium chloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    human rhinovirus (polyvalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KR-22809 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit Viral 3C Protease for Human Rhinovirus Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for Human Rhinovirus Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    OBR-5340 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PL-402 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Polymer for Viral Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Recombinant Peptide to Inhibit Viral 2A Cysteine Protease for Rhinovirus Infection - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    rhinovirus vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit PI4KB for Rhinovirus Infection - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit 3C Protease for Rhinovirus Infection - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    vapendavir - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VXX-003 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Rhinovirus Infections - Dormant Projects
    Rhinovirus Infections - Product Development Milestones
    Featured News & Press Releases
    Feb 13, 2017: Aviragen Therapeutics Announces Top-Line Results from Phase 2b SPIRITUS Trial of Vapendavir
    Oct 10, 2016: Aviragen Therapeutics to Host KOL Meeting on HRV Infections on October 13, 2016 in New York
    Mar 03, 2015: Biota Commences Dosing in Vapendavir SPIRITUS Phase 2b Trial
    Mar 28, 2012: Biota Announces Positive Phase IIb Data In Asthma Patients With Human Rhinovirus Infection
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Rhinovirus Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Rhinovirus Infections - Pipeline by AIMM Therapeutics BV, H1 2017
    Rhinovirus Infections - Pipeline by AstraZeneca Plc, H1 2017
    Rhinovirus Infections - Pipeline by Aviragen Therapeutics Inc, H1 2017
    Rhinovirus Infections - Pipeline by Biological Mimetics Inc, H1 2017
    Rhinovirus Infections - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Rhinovirus Infections - Pipeline by Novartis AG, H1 2017
    Rhinovirus Infections - Pipeline by Prokarium Ltd, H1 2017
    Rhinovirus Infections - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Rhinovirus Infections, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    AIMM Therapeutics BV
    AstraZeneca Plc
    Aviragen Therapeutics Inc
    Biological Mimetics Inc
    Boehringer Ingelheim GmbH
    Novartis AG
    Prokarium Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//rhinovirus-infections-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//rhinovirus-infections-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//rhinovirus-infections-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments